

020 RECEIVED 07 OCT 2005

Sheet 1 of 1 (10/7/05)

Form PTO-1449 INFORMATION DISCLOSURE CITATION IN AN APPLICATION (Use several sheets if necessary)				ATTY. DOCKET NO. 4518-0111PUS1		APPLICATION NO. 10/552324	
				APPLICANT LOIBNER, Hans et al.			
				FILING DATE October 7, 2005		GROUP	

U.S. PATENT DOCUMENTS							
EXAMINER INITIAL	DOCUMENT NUMBER	Kind	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE
	US						
	US						
	US						
	US						
	US						
	US						
	US						
	US						
	US						
	US						

FOREIGN PATENT DOCUMENTS								
Office	DOCUMENT NUMBER	Kind	DATE	COUNTRY	CLASS	SUB CLASS	TRANSLATION	
							YES	NO
DE	10059930	A	2002-05-29	DE				
EP	0285059	A	1988-10-05	EPO				
EP	0759442	A	1997-02-26	EPO				
WO	93/24647	a	1993-12-09	WO				
WO	00/41722	A	2000-07-20	WO				
WO	01/35989	A	2001-05-25	WO				
WO	03/097663	A	2003-11-27	WO				

OTHER DOCUMENTS	
(Include Name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	
	SALEH, M. et al., "Generation of a human anti-idiotypic antibody that mimics the GD2 antigen" Journal of Immunology, Vol. 151, No. 6, 15 September 1993, pp. 3396-3398
	BRUMEANU T.D. et al., "Engineering of doubly antigenized immunoglobulins expressing T and B viral epitopes" Immunotechnology, Vol. 2, No. 2, 1996, pp. 85-95
	WAXENECKER G. et al., "Qualitative and Quantitative Dissection of the Immune Response to the Cancer Vaccine Candidates IGN101 and IGN301" Proceedings of the Annual Meeting of the American Association for Cancer Research, Vol. 43, March 2002, p. 560
	WALLICK, C.S. et al., "Glycosylation of a VH Residue of a Monoclonal Antibody Against Alpha(1-6) Dextran Increases its Affinity for Antigen" Journal of Experimental Medicine, Vol. 168, September 1988, pp. 1099-1109

EXAMINER /Lynn Bristol/	DATE CONSIDERED 12/30/2007
----------------------------	-------------------------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with M.P.E.P. 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449				ATTY. DOCKET NO. 4518-0111PUS1		APPLICATION NO. 10/552,324			
INFORMATION DISCLOSURE CITATION IN AN APPLICATION <small>(Use several sheets if necessary)</small>				APPLICANT LOIBNER, Hans ET AL					
<div style="border: 1px solid black; border-radius: 50%; padding: 10px; display: inline-block; text-align: center;"> OIPE MAY 22 2006 U.S. PATENT & TRADEMARK OFFICE </div>				FILING DATE October 7, 2005		GROUP			
U.S. PATENT DOCUMENTS									
EXAMINER INITIAL	DOCUMENT NUMBER	Kind	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE		
LAB	US 5977315	A	1999-11-02	CHATTERJEE et al.					
	US								
	US								
	US								
	US								
	US								
	US								
	US								
	US								
FOREIGN PATENT DOCUMENTS									
	Office	DOCUMENT NUMBER	Kind	DATE	COUNTRY	CLASS	SUB CLASS	TRANSLATION	
								YES	NO
LAB ↓	WO	97/40140	A1	1997-10-30	PC				
	WO	01/21796	A2	2001-03-29	PC				
OTHER DOCUMENTS <small>(Include Name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.)</small>									
LAB ↓	STEINITZ, M. et al., "Human monoclonal anti-idiotypic antibodies. I. Establishment of immortalized cell lines from a tumor patient treated with mouse monoclonal antibodies", Journal of Immunology, 11-15-1988, Vol. 141, No. 10, pp. 3516-3522 (Abstract)								
	FAGERBERG, J. et al., "Humoral anti-idiotypic and anti-anti-idiotypic immune response in cancer patients treated with monoclonal antibody 17-1A", Cancer Immunology, Immunotherapy: CII, 1996, Vol. 42, No. 2, pp. 81-87 (Abstract)								
EXAMINER /Lynn Bristol/					DATE CONSIDERED 12/30/2007				
EXAMINER: Initial if citation considered, whether or not citation is in conformance with M.P.E.P. 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.									

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)			Complete if Known		
			Application Number	10/552,324-Conf. #8937	
			Filing Date	October 7, 2005	
			First Named Inventor	Hans LOIBNER	
			Art Unit	N/A	
			Examiner Name	Not Yet Assigned	
Sheet	1	of	1	Attorney Docket Number	4518-0111PUS1

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
LAB	AA*	US-5,977,315	11-02-1999	Chatterjee et al.	
	AB*	US-20040181475-A1	09-16-2004	Haroon	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
LAB	BA	EP-0285059	10-05-1988	Wistar Inst		
	BB	WO-0121796	03-29-2001	Genetics Inst		
	BC	WO-0740140	10-30-1997	Wistar Inst		
LAB	BD	WO-0041722	07-20-2000	Igeneon Gmbh et al.		
	BE	DE-10059930	05-29-2002	Fischer Peter et al.		
	BF	EP-0759442	02-26-1997	Oncogen		
	BG	WO-0135989	05-25-2001	Igeneon Krebs Immuntherapie Fo et al.		
	BH	WO-9324647	12-09-1993	Sandoz Ag et al.		
	BI	WO-03097663	11-27-2003	Igeneon Krebs Immuntherapie Fo et al.		
	BJ	CA-2360382	07-20-2000	Igeneon Krebs Immuntherapie Fo		
	BK	CA-2391927	05-25-2001	Igeneon Krebs Immuntherapie Fo		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. * CITE NO.: Those application(s) which are marked with an single asterisk (*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was filed after June 30, 2003 or is available in the IFW. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		T ²
LAB	CA	BRUMEANU, T.-D. et al., "Engineering of doubly antigenized immunoglobulins expressing T and B viral epitopes," Immunotechnology, 1996, Vol. 2, pp. 85-95.		
	CB	SALEH, M. et al., "Generation of a human anti-idiotypic antibody that mimics the GD2 antigen" Journal of Immunology, Vol. 151, No. 6, 15 September 1993, pp. 3390-3398.		
	CC	WAXENECKER, G. et al., "Qualitative and quantitative dissection of the immune response to the cancer vaccine candidates IGN101 and IGN301" Proceedings of the Annual Meeting of the American Association for Cancer Research, Vol 43, March 2002, pp. 560.		
	CD	WALLICK, C.S. et al., "Glycosylation of a VH residue of a monoclonal antibody against alpha (1-6) dextran increases its affinity for antigen" Journal of Experimental Medicine, Vol. 168, September 1988, pp. 1099-1109.		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature	/Lynn Bristol/	Date Considered	12/30/2007
--------------------	----------------	-----------------	------------